Coronary artery disease High-density lipoprotein cholesterol , coronary artery disease , and cardiovascular mortality

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CLINICAL RESEARCH Coronary artery disease

[1]  S. Hazen,et al.  Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[2]  H. Brenner,et al.  Proinflammatory Cytokines, Adiponectin, and Increased Risk of Primary Cardiovascular Events in Diabetic Patients With or Without Renal Dysfunction , 2013, Diabetes Care.

[3]  D. Carroll,et al.  Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography. , 2013, European heart journal.

[4]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[5]  J. Jukema,et al.  Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. , 2012, European heart journal.

[6]  Ming-Dauh Wang,et al.  Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. , 2011, JAMA.

[7]  A. Khera,et al.  The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. , 2011, Journal of the American College of Cardiology.

[8]  A. Kontush,et al.  Biological activities of HDL subpopulations and their relevance to cardiovascular disease. , 2011, Trends in molecular medicine.

[9]  A. Akhmedov,et al.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. , 2011, The Journal of clinical investigation.

[10]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[11]  S. Reddy,et al.  HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms , 2011, Nature Reviews Cardiology.

[12]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[13]  P. Toth.  Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis , 2011 .

[14]  B. Gersh.  HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial , 2011 .

[15]  J. Kastelein,et al.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? , 2010, Journal of Lipid Research.

[16]  P. Barter,et al.  Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database , 2010, Journal of Lipid Research.

[17]  Christopher P Cannon,et al.  High-density lipoprotein and coronary heart disease: current and future therapies. , 2010, Journal of the American College of Cardiology.

[18]  Costantina Manes,et al.  Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.

[19]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[20]  D. Tousoulis,et al.  Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. , 2009, JAMA.

[21]  J. Liao.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.

[22]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[23]  G. Niccoli,et al.  Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. , 2008, European heart journal.

[24]  H. Brenner,et al.  Changes of cardiovascular risk factors and their implications in subsequent birth cohorts of older adults in Germany: a life course approach , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[25]  A. Gotto,et al.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.

[26]  D. Gordon,et al.  High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .

[27]  F. Cambien,et al.  Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. , 2003, The New England journal of medicine.

[28]  W. März,et al.  Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. , 2001, Pharmacogenomics.

[29]  A. von Eckardstein,et al.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.

[30]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.